3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase NA
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Squamous Cell Carcinoma of Head and Neck
24
Head and Neck Neoplasms
21
Lung Neoplasms
19
Neoplasms
18
Stomach Neoplasms
15
Urinary Bladder Neoplasms
14
Uterine Cervical Neoplasms
11
Small Cell Lung Carcinoma
11
Ovarian Neoplasms
11
Esophageal Neoplasms
11
Colorectal Neoplasms
11
Pancreatic Neoplasms
10
Biliary Tract Neoplasms
10
Carcinoma, Transitional Cell
9
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
8
Breast Neoplasms
8
Oropharyngeal Neoplasms
7
Mesothelioma, Malignant
7
Melanoma
7
Cholangiocarcinoma
7
Carcinoma, Squamous Cell
6
Recurrence
5
Nasopharyngeal Carcinoma
5
Mesothelioma
5
Esophageal Squamous Cell Carcinoma
5
Carcinoma
5
Nasopharyngeal Neoplasms
4
Mouth Neoplasms
4
Interventions
talimogene laherparepvec
1
rilotumumab
1
ganitumab
1
camrelizumab
1
Thiostrepton
1
Silver Nitrate
1
Nivolumab
1
Etoposide
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pleural Effusion, Malignant
×
Cisplatin
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts